title: Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: Relevant differences using the same treatment.
authors.affiliation: Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Juul.vandenReek@Radboudumc.nl.
authors.forename: Juul M P A
authors.initials: JM
authors.lastname: van den Reek
authors.affiliation: Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Philippe A R R
authors.initials: PA
authors.lastname: Pijls
authors.affiliation: Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Marcia
authors.initials: M
authors.lastname: Tummers
authors.affiliation: Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Piet C L M
authors.initials: PC
authors.lastname: van Riel
authors.affiliation: Radboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Wietske
authors.initials: W
authors.lastname: Kievit
authors.affiliation: Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Frank
authors.initials: F
authors.lastname: Hoentjen
authors.affiliation: Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Elke M G J
authors.initials: EM
authors.lastname: de Jong
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016001:Confidence Intervals; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D016016:Proportional Hazards Models; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D012042:Registries; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab